Unrivaled Brands Inc (OTCQX:UNRV) has announced its second-quarter financial results, revealing significant year-over-year revenue and gross profit growth. The West Coast cannabis company generated total revenue of $17.56 million in the three months ended June 30, including retail revenue of $10.95 million and cultivation/distribution revenue of $6.61 million. That’s more than six times the $2.87 million of revenue achieved during the same period of 2021, of which $2.32 million was retail revenue. Gross profit was $8.27 million, more than triple the $2.72 million profit it made in the year-ago period.
Dore Copper Mining Corp announced it has appointed 15-year mining veteran Nicholas Kwong to the role of Chief Operating Officer effective immediately. Kwong’s experience in the mining industry has largely been in gold and base metals in North America, Australia, Latin America and Saudi Arabia. He has held numerous site and corporate roles for New Gold, including director, technical services, and subsequently joined Ma'aden Gold in Saudi Arabia as general manager of the Sukhaybarat and Bulghah gold mines.
Nextech AR Solutions Corp has reported its financial and operating results for the second quarter ending June 30, 2022, showing continued record growth in 3D modelling for eCommerce and its Web3.0 business. The provider of augmented reality (AR) solutions said revenue from Web3.0 and 3D modelling grew 40% quarter-on-quarter in the three months to June 30, 2022. It added that annual recurring revenue and repeat revenue was $1.6 million, also a record for the company. Looking into the third quarter, Nextech said its newly-implemented shares for services plan will reduce its monthly burn from about $1 million per month to approximately $500,000 per month, extending its cash runway for at least 12 months.
Westwater Resources Inc (NYSE-A:WWR) has applauded the historic Inflation Reduction Act signed into law by President Joe Biden on August 16, 2022 which includes an investment of $369 billion in climate programs that should, directly and indirectly, benefit Westwater. In a statement, Terence Cryan, executive chairman of Westwater said: "Our company is uniquely positioned to benefit from this legislation. The legislation provides direct benefits in the form of a Production Tax Credit for future production of advanced anode material from our Kellyton Graphite Plant. In addition, the legislation should increase demand for domestically produced graphite and vanadium, both of which are contained in our Coosa Graphite Deposit - The IRA is good news for Westwater." The key provision directly benefiting Westwater is the Production Tax Credit for Critical Minerals, which provides a 10% tax credit for the costs of producing certain critical minerals, including graphite and vanadium.
Universal Ibogaine Inc (TSX-V:IBO) said it is targeting early October for the re-opening of its Winnipeg addiction treatment facility, the Kelburn Recovery Centre, after it was closed in April due to damage from an on-site sewer backup. Before repairs could be completed, abnormally high spring rainfall and snow melt runoff resulted in the flooding of the Red River, which forced local road closures but no additional damage to the facility. Repairs are now underway and proceeds to be received under Kelburn's insurance coverage are being finalized. The company said it has been developing a best-in-class evidence-based holistic addiction recovery program to deliver at the Kelburn facility which, upon Health Canada approval, may involve ibogaine: a plant-derived medicine used in addiction treatment and has been shown to deliver detoxification from opioids, heroin and other substances, and can provide several months free of drug cravings.
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) said it has completed significant groundwork to support multi-kilogram production for use in the final drug production of PD-001, its patented, oral version of cepharanthine, to treat responsive cancers and COVID-19. Completion of this lot, slated for September 2022, advances PharmaDrug’s plans to potential phase 2 clinical studies. PharmaDrug has engaged Genvion Corporation to complete stability testing and forced degradation studies in support of future investigational new drug (IND) filings to the US Food and Drug Administration (FDA).
CleanSpark Inc (NASDAQ:CLSK) announced that it has completed the acquisition of an active bitcoin mining facility located in Washington, Georgia. The sustainable bitcoin mining and energy technology company said the site is expected to add 2.6 exahashes per second (EH/s) to CleanSpark’s hashrate once all 86 megawatts (MW) of predominantly carbon-free power is fully operational in 2023. “This is a tremendous opportunity for CleanSpark and our shareholders and we are thrilled to be moving so quickly on the deployment of this site,” CleanSpark executive chairman Matt Schultz said in a statement.
Aion Therapeutic Inc has said it anticipates being late in filing its annual audited consolidated financial statements and related annual management discussion and analysis (MD&A) for the year ended April 30, 2022, by the prescribed deadline of August 29, 2022. On August 10, 2022, the company changed its auditors from Harbourside CPA LLP to Kreston GTA LLP. As a result of the change of auditor of the issuer within such close proximity to the filing deadline, the company and auditor require additional time to file the annual financial statements and MD&A. The company anticipates that it will be in a position to file the annual financial statements and related MD&A on or prior to October 31, 2022. Accordingly, the company has made an application with the applicable securities regulators under National Policy 12-203 -- Cease Trade Orders for Continuous Disclosure Defaults requesting that a management cease trade order be imposed in respect of the anticipated late filing rather than an issuer cease trade order. The issuance of a management cease trade order does not affect the ability of persons who have not been directors, officers or insiders of the company to trade in their securities.
Kootenay Silver Inc has clarified that a news release disseminated on August 12, 2022, headlined "Kootenay Resources Inc. Announces Private Placement financing of up to $800,000" is related to Kootenay Resources Inc a private reporting issuer and is not related to the common stock of Kootenay Silver, a TSX Venture listed company. Kootenay Resources is an exploration company actively engaged in the exploration and discovery mineral projects in British Columbia, Canada and was formed as a spin-out of Kootenay Silver in which prospective Canadian assets were transferred to Kootenay Resources. The transaction was completed in October 2021, Kootenay Silver currently holds around 3.2 million common shares of Kootenay Resources.
Wishpond Technologies Ltd said the TSX Venture Exchange has accepted for filing the company's proposal to issue 283,677 common shares of the company at a deemed price of 59.7 cents per share in consideration of the earnout payments to AtlasMind Inc. as outlined in the asset purchase agreement dated August 27, 2021. The exchange has also accepted for filing the company's proposal to issue an aggregate of 1,076,405 shares at a deemed price of 64.42 cents per share in consideration of the earnout payments to the owners of PersistIQ as outlined in the share purchase agreement dated February 26, 2021.
Usha Resources Ltd (TSX-V:USHA) has announced that Deepak Varshney, its CEO, will present live at VirtualInvestorConferences.com on August 23, 2022, at 1.30pm PDT/4.30pm EDT via the following link: https://bit.ly/3JSF8GE. This battery metals-focused event is co-sponsored by Virtual Investor Conferences and Independent Investment Research LLC. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
Todos Medical Ltd announced that its majority-owned joint venture 3CL Pharma Ltd reported the preprint in ResearchGate of results from the first 100-participant study from an IRB-waived market research study entitled "The Value of 3CL Protease Inhibitor Supplementation in Long Haul Syndrome Patients?" overseen by Dr. Dorit Arad in concert with Andrew Blumenthal, Todos CEO. Participants in the study are primarily patients with Post-Acute Sequelae of COVID as well as participants with acute COVID infection. The results to date indicate the participants appear to experience benefit after supplementation with 3CL protease inhibitor immune support supplement Tollovid. The publication preprint can be viewed here.
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) announced it has updated its corporate slide deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131. Philip Young, CEO of Lobe Sciences stated: "We have made significant progress toward initiating our first human trials with our proprietary psilocin analog L-130 and pre-clinical plans for L-131. These updates can be found at our company website at https://www.lobesciences.com/corporate-profile/company-presentation/. We believe that Lobe is beginning to be recognized as one of the leading companies developing stable psilocin compounds as noted in leading Biotech publications such as Fierce Biotech. This is an exciting time for all stakeholders and I look forward to continuing to update the investment community as we advance our plans for developing novel drugs for patients around the globe."
Vyant Bio (NASDAQ:VYNT) Inc announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 22, 2022. Vyant Bio (NASDAQ:VYNT) will host an investor conference call and webcast on Monday, August 22, 2022 at 4:30 pm ET. Jay Roberts, CEO, Andy LaFrence, CFO, and Robert Fremeau, CSO, of Vyant Bio (NASDAQ:VYNT) will provide an update on the business, scientific, and financial progress made during the second quarter and first half of 2022. Management will also be taking audience questions that are submitted in advance only. Investors may submit written questions via e-mail to: info@skylineccg.com. Participants may dial in at 1-877-545-0523 using the Conference ID: 46428. A Webcast will be available at https://www.webcaster4.com/Webcast/Page/2756/46428. The event will be recorded and available for replay. The conference call and webcast details are also included inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com.